Lupin's arm receives USFDA approval for generic Topicort Ointment

07 Dec 2016 Evaluate

Lupin’s US subsidiary, Lupin Pharmaceuticals, Inc. (collectively Lupin) has received final approval for its Desoximetasone Ointment USP, 0.25% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharmaceuticals, Inc.’s Topicort Ointment, 0.25%. Topicort had US sales of $14.4 million, as per IMS MAT September 2016.

Lupin’s Desoximetasone Ointment USP, 0.25% is the AB rated generic equivalent of Taro Pharmaceuticals, Inc.’s Topicort Ointment, 0.25%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.


Lupin Share Price

2069.95 26.65 (1.30%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.